Aripiprazole lauroxil (RDC3317; RDC-3317; ALKS 9070; ALKS-9072; Abilify; Aristada) is a long-acting injectable atypical antipsychotic approved in 2015 by FDA mainly for the treatment of schizophrenia and bipolar disorder. It can also be used as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Aripiprazole lauroxil is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to six weeks for the treatment of schizophrenia.

纯度：≥98%

CAS：1259305-29-7